Universität zu Köln

von Stebut, Esther, Reich, Kristian, Thaci, Diamant ORCID: 0000-0001-8513-550X, Koenig, Wolfgang, Pinter, Andreas, Koerber, Andreas, Rassaf, Tienush, Waisman, Ari, Mani, Venkatesh ORCID: 0000-0002-0432-2918, Yates, Denise, Frueh, Jennifer, Sieder, Christian, Melzer, Nima, Mehta, Nehal N. and Gori, Tommaso (2019). Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks. J. Invest. Dermatol., 139 (5). S. 1054 - 1063. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1523-1747

Full text not available from this repository.

Abstract

Psoriasis increases the risk of cardiovascular (CV) disease. Secukinumab, a fully human monoclonal antibody against IL-17A, shows significant efficacy in psoriasis, but effects on CV markers are unknown. CARIMA (Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated with Secukinumab) was a 52-week, randomized, double-blind, placebo-controlled, exploratory trial in patients with moderate to severe plaque psoriasis without clinical CV disease. Patients were randomly assigned to receive 300 mg or 150 mg secukinumab until week 52 or to receive placebo until week 12 and then 300 mg or 150 mg secukinumab until week 52. The primary outcome was endothelial function measured by flow-mediated dilation (FMD). Baseline FMD was significantly lower in psoriasis patients than healthy volunteers (4.4 +/- 3.9% vs. 6.1 +/- 3.3%, P = 0.01). At week 12, baseline-adjusted mean FMD was numerically higher in patients receiving secukinumab versus those receiving placebo, but this difference (300-mg group, +1.2%; 150-mg group, +0.76%; P = 0.223 and P = 0.403 by analysis of covariance) did not reach significance. At week 52, FMD increased across groups. FMD was significantly higher than baseline in patients receiving the label dose of 300 mg secukinumab for 52 weeks (+2.1%, 95% confidence interval = 0.8-3.3; P = 0.0022). Other relevant CV markers were unchanged. CARIMA indicates that secukinumab might have a beneficial effect on CV risk by improving the endothelial function of patients with plaque psoriasis.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code von Stebut, Esther UNSPECIFIED UNSPECIFIED UNSPECIFIED Reich, Kristian UNSPECIFIED UNSPECIFIED UNSPECIFIED Thaci, Diamant UNSPECIFIED orcid.org/0000-0001-8513-550X UNSPECIFIED Koenig, Wolfgang UNSPECIFIED UNSPECIFIED UNSPECIFIED Pinter, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Koerber, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Rassaf, Tienush UNSPECIFIED UNSPECIFIED UNSPECIFIED Waisman, Ari UNSPECIFIED UNSPECIFIED UNSPECIFIED Mani, Venkatesh UNSPECIFIED orcid.org/0000-0002-0432-2918 UNSPECIFIED Yates, Denise UNSPECIFIED UNSPECIFIED UNSPECIFIED Frueh, Jennifer UNSPECIFIED UNSPECIFIED UNSPECIFIED Sieder, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Melzer, Nima UNSPECIFIED UNSPECIFIED UNSPECIFIED Mehta, Nehal N. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gori, Tommaso UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-150050
DOI:	10.1016/j.jid.2018.10.042
Journal or Publication Title:	J. Invest. Dermatol.
Volume:	139
Number:	5
Page Range:	S. 1054 - 1063
Date:	2019
Publisher:	ELSEVIER SCIENCE INC
Place of Publication:	NEW YORK
ISSN:	1523-1747
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PULSE-WAVE VELOCITY; ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY; AORTIC VASCULAR INFLAMMATION; FACTOR-ALPHA INHIBITORS; FLOW-MEDIATED DILATION; REFERENCE VALUES; SYSTEMIC INFLAMMATION; PLAQUE PSORIASIS; DOUBLE-BLIND; RISK Multiple languages Dermatology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/15005